Whole-exome sequencing in a subject with fluctuating neuropsychiatric symptoms, immunoglobulin G1 deficiency, and subsequent development of Crohn's disease: a case report
- PMID: 35538558
- PMCID: PMC9092677
- DOI: 10.1186/s13256-022-03404-9
Whole-exome sequencing in a subject with fluctuating neuropsychiatric symptoms, immunoglobulin G1 deficiency, and subsequent development of Crohn's disease: a case report
Abstract
Background: Mutations or polymorphisms of genes that are associated with inflammasome functions are known to predispose individuals to Crohn's disease and likely affect clinical presentations and responses to therapeutic agents in patients with Crohn's disease. The presence of additional gene mutations/polymorphisms that can modify immune responses may further affect clinical features, making diagnosis and management of Crohn's disease even more challenging. Whole-exome sequencing is expected to be instrumental in understanding atypical presentations of Crohn's disease and the selection of therapeutic measures, especially when multiple gene mutations/polymorphisms affect patients with Crohn's disease. We report the case of a non-Hispanic Caucasian female patient with Crohn's disease who was initially diagnosed with pediatric acute-onset neuropsychiatric syndrome with fluctuating anxiety symptoms at 9 years of age. This patient was initially managed with pulse oral corticosteroid treatment and then intravenous immunoglobulin due to her immunoglobulin G1 deficiency. At 15 years of age, she was diagnosed with Crohn's disease, following onset of acute abdomen. Treatment with oral corticosteroid and then tumor necrosis factor-α blockers (adalimumab and infliximab) led to remission of Crohn's disease. However, she continued to suffer from chronic abdominal pain, persistent headache, general fatigue, and joint ache involving multiple joints. Extensive gastrointestinal workup was unrevealing, but whole-exome sequencing identified two autosomal dominant gene variants: NLRP12 (loss of function) and IRF2BP2 (gain of function). Based on whole-exome sequencing findings, infliximab was discontinued and anakinra, an interleukin-1β blocker, was started, rendering marked improvement of her clinical symptoms. However, Crohn's disease lesions recurred following Yersinia enterocolitis. The patient was successfully treated with a blocker of interleukin-12p40 (ustekinumab), and anakinra was discontinued following remission of her Crohn's disease lesions.
Conclusion: Loss-of-function mutation of NRLRP12 gene augments production of interleukin-1β and tumor necrosis factor-α, while gain-of-function mutation of IRF2BP2 impairs cytokine production and B cell differentiation. We propose that the presence of these two autosomal dominant variants caused an atypical clinical presentation of Crohn's disease.
Keywords: Crohn’s disease; IRF2BP2; Interleukin-1β; NLRP12; Pediatric acute-onset neuropsychiatric syndrome; Tumor necrosis factor-α; Whole-exome sequencing.
© 2022. The Author(s).
Conflict of interest statement
There are no financial or nonfinancial competing interests to declare.
Figures
Similar articles
-
Co-occurrence of oral pemphigus vulgaris and herpes simplex virus infection in a young patient with Crohn's disease: report of a rare case of oral lesions during anti-TFN alpha and immunomodulator therapy.Int J Colorectal Dis. 2024 Aug 6;39(1):125. doi: 10.1007/s00384-024-04673-0. Int J Colorectal Dis. 2024. PMID: 39105861 Free PMC article.
-
Lymphomatoid Papulosis Type B in a Patient with Crohn's Disease Treated with TNF-Alpha Inhibitors Infliximab and Adalimumab.Acta Dermatovenerol Croat. 2019 Sep;27(3):202-204. Acta Dermatovenerol Croat. 2019. PMID: 31542070
-
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5. Acta Dermatovenerol Croat. 2016. PMID: 27149138
-
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. BioDrugs. 2010. PMID: 21175228 Review.
-
Fistulising skin metastases in Crohn's disease: a case report and review of the literature.J Med Case Rep. 2024 May 19;18(1):252. doi: 10.1186/s13256-024-04569-1. J Med Case Rep. 2024. PMID: 38762485 Free PMC article. Review.
Cited by
-
Pediatric Acute-Onset Neuropsychiatric Syndrome: Current Perspectives.Neuropsychiatr Dis Treat. 2023 May 24;19:1221-1250. doi: 10.2147/NDT.S362202. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 37251418 Free PMC article. Review.
-
Eight Cases of Pediatric Acute-Onset Neuropsychiatric Syndrome with Inflammatory Bowel Disease: Immunologic Intersections.Dev Neurosci. 2025;47(4):287-302. doi: 10.1159/000543969. Epub 2025 Feb 10. Dev Neurosci. 2025. PMID: 39929162 Free PMC article.
-
Identification of a Novel NLRP12 Frameshift Mutation (Val730Glyfs∗41) by Whole-Exome Sequencing in Patients with Crohn's Disease.Hum Mutat. 2024 Feb 23;2024:5573272. doi: 10.1155/2024/5573272. eCollection 2024. Hum Mutat. 2024. PMID: 40225939 Free PMC article.
References
-
- Chen L, Wilson JE, Koenigsknecht MJ, Chou WC, Montgomery SA, Truax AD, Brickey WJ, Packey CD, Maharshak N, Matsushima GK, et al. NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth. Nat Immunol. 2017;18(5):541–551. doi: 10.1038/ni.3690. - DOI - PMC - PubMed
-
- Dellaporta E, Lazaridis LD, Koussoulas V, Netea MG, Giamarellos-Bourboulis EJ, Triantafyllou K. Association between genotypes of rs34436714 of NLRP12 and serum tumor necrosis factor-alpha in inflammatory bowel disease: a case-control study. Medicine (Baltimore) 2019;98(23):e15913. doi: 10.1097/MD.0000000000015913. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical